STOCK TITAN
  1. Home
  2. News
  3. ADMP

Adamis Pharmaceuticals Corporation - ADMP STOCK NEWS

Welcome to our dedicated page for Adamis Pharmaceuticals Corporation news (Ticker: ADMP), a resource for investors and traders seeking the latest updates and insights on Adamis Pharmaceuticals Corporation stock.

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) develops critical therapies for opioid overdose, respiratory conditions, and immune disorders. This dedicated news hub provides investors and healthcare professionals with essential updates on the company's FDA-approved treatments, pipeline developments, and strategic initiatives.

Access verified information about ZIMHI® naloxone injections for opioid emergencies, SYMJEPI® epinephrine delivery systems for allergic reactions, and emerging respiratory therapies. Track progress on clinical-stage programs including DPI-125 for opioid use disorder and novel inhalers for asthma/COPD management.

Our curated news collection covers:
• Regulatory milestones and product approvals
• Clinical trial developments across therapeutic areas
• Strategic partnerships with government and research entities
• Financial updates and Nasdaq compliance efforts

Bookmark this page for reliable updates on Adamis' mission to address public health challenges through innovative biopharmaceutical solutions. Check regularly for new developments in life-saving emergency treatments and chronic disease management therapies.

News

Adamis Pharmaceuticals Changes Name to DMK Pharmaceuticals to Reflect New Strategic Focus

Rhea-AI Summary
Adamis Pharmaceuticals Corporation changes its name to DMK Pharmaceuticals Corporation and will begin trading under the ticker symbol 'DMK' on September 8, 2023. The company's new strategic focus is on advancing small molecules for the treatment of substance use disorders. DPI-125, the company's lead clinical stage compound, is expected to have several significant milestones by the end of 2024. These include a transdermal delivery system, safety study results compared to fentanyl, pharmacokinetic study results in humans, and abuse liability study results compared to current treatments for OUD and pain relief.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.3%
Tags
none
-
News

Adamis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Rhea-AI Summary
Adamis Pharmaceuticals Corporation announces Q2 2023 financial results and recent corporate developments
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
News

Adamis Pharmaceuticals Announces Closing of $8.0 Million Public Offering

Rhea-AI Summary
Adamis Pharmaceuticals Corporation has closed its public offering of 5,930,000 units, each consisting of one share of common stock and one warrant. The units were sold at a public offering price of $1.35 per unit, resulting in gross proceeds of approximately $8.0 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.18%
Tags
offering
News

Adamis Pharmaceuticals Announces Pricing of $8.0 Million Public Offering

Rhea-AI Summary
Adamis Pharmaceuticals Corporation announces pricing of public offering at $1.35 per unit, expected to raise approximately $8.0 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-66.67%
Tags
offering
-
News

Adamis Pharmaceuticals to Fund ZIMHI® Clinical Study with University of Leiden Opioid Expert

Rhea-AI Summary
Adamis Pharmaceuticals commits to funding an unrestricted research grant to the Leiden University Medical Center (LUMC) Anesthesia and Pain Research Unit. The funding will support the work of Dr. Albert Dahan, an expert on opioid-induced respiratory depression. The collaboration aims to assess the efficacy of 5mg intramuscular ZIMHI versus 4mg intranasal naloxone in reversing fentanyl-induced respiratory depression.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.58%
Tags
clinical trial
-
News

Adamis Pharmaceuticals Announces NIH Grant Funding for the Treatment of Alcohol Use Disorder

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.27%
Tags
none
News

Adamis Pharmaceuticals Participated in White House Meeting Regarding Opioid Overdose Prevention

Rhea-AI Summary
Adamis Pharmaceuticals CEO participates in White House Roundtable on Opioid Crisis
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.32%
Tags
none
-
News

Adamis Pharmaceuticals Announces Closing of the Merger with DMK Pharmaceuticals

Rhea-AI Summary
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) has announced the completion of its merger with DMK Pharmaceuticals Corporation. The combined company will focus on increasing sales of Adamis' commercial products and advancing DMK's lead clinical stage compound, DPI-125, for the treatment of opioid use disorder (OUD). Ebrahim Versi, CEO of DMK, has been named CEO of Adamis and Chairman of the Board of Directors. The global opioid market in 2021 was reported to be greater than $22 billion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.2%
Tags
acquisition
-
News

Adamis Pharmaceuticals Announces Reverse Stock Split

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-28.57%
Tags
none
News

Adamis Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
Stock ADMP logo
Adamis Pharmaceuticals Corporation

Nasdaq:ADMP

ADMP Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

ADMP Stock Data

7.25M
9.14M
7.81%
16.59%
1.3%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States
San Diego